Detailed Information

Cited 10 time in webofscience Cited 9 time in scopus
Metadata Downloads

A randomized study of cisplatin and 5-FU hepatic arterial infusion chemotherapy with or without adriamycin for advanced hepatocellular carcinoma

Authors
Song, Myeong JunBae, Si HyunChun, Ho JongChoi, Jong YoungYoon, Seung KewPark, Jun YoungHan, Kwang HyubKim, Young SeokYim, Hyung JoonUm, Soon HoChung, Woo JinHwang, Jae SeokCho, Sung-BumEun, Jong Ryul
Issue Date
Apr-2015
Publisher
SPRINGER
Keywords
Hepatocellular carcinoma; Hepatic arterial infusion chemotherapy; 5-Fluorouracil; Cisplatin
Citation
CANCER CHEMOTHERAPY AND PHARMACOLOGY, v.75, no.4, pp.739 - 746
Indexed
SCIE
SCOPUS
Journal Title
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume
75
Number
4
Start Page
739
End Page
746
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/8039
DOI
10.1007/s00280-015-2692-0
ISSN
0344-5704
Abstract
This multicenter, randomized, open-labeled, clinical trial evaluated the efficacy and safety of cisplatin/5-fluorouracil (5-FU) hepatic arterial infusion chemotherapy (CF-HAIC) versus adriamycin adding to CF-HAIC (ACF-HAIC) in advanced HCC patients. Fifty-six patients with advanced HCC were randomized to two treatment groups: (1) CF-HAIC group [n = 29, 5-FU, 500 mg/m(2) on days 1-3, and cisplatin, 60 mg/m(2) on day 2] and (2) ACF-HAIC group [n = 27, adriamycin, 50 mg/m(2) on day 1, 5-FU, 500 mg/m(2) on days 1-3, and cisplatin, 60 mg/m(2) on day 2] every 4 weeks via an implantable port system. Primary efficacy endpoint was overall survival (OS). Treatment response and time to progression were secondary endpoints. Treatment response rates did not differ significantly between the two treatment groups. Time to progression (5.4 vs. 5.8 months, P = 0.863) and OS (11.1 vs. 8.8 months, P = 0.448) were not significantly different. When the factors affecting patient OS were analyzed, disease control rate [P < 0.001, HR 6.437 (95 % CI 2.580-16.064)] was independently associated with OS. Age (a parts per thousand yen60 years) and serum AFP level (a parts per thousand yen200 ng/dL) also were significant factors for OS [P = 0.007, HR 4.945 (95 % CI 1.543-15.850), P = 0.048, HR 2.677 (95 % CI 1.010-7.095), respectively]. Grade 4 treatment-related toxicity and mortality was not observed in both groups. Although both HAIC regimens are safe and effective in patients with advanced HCC, HAIC adding adriamycin did not show delayed tumor progression and survival benefit compared to CF-HAIC in advanced HCC.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Yim, Hyung Joon photo

Yim, Hyung Joon
Ansan Hospital (Department of Gastroenterology and Hepatology, Ansan Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE